治水千年道，减重有新方：解码全球首个申报上市的GCG/GLP-1双靶减重药物玛仕度肽

Core Viewpoint - The article discusses the obesity epidemic in China, highlighting the need for innovative solutions to address the health issues associated with obesity, particularly focusing on the dual-target weight loss drug, Ma Shidu Tie, which is expected to be approved soon [7][27][41]. Group 1: Obesity and Health Issues - Approximately 50% of adults in China are overweight or obese, with 81.8% of the obese population also suffering from fatty liver disease [7][8]. - The liver, as a metabolic center, can lead to severe health problems when overwhelmed by fat, including diabetes, hypertension, and cardiovascular diseases [9][10]. Group 2: Traditional Weight Loss Interventions - Traditional weight loss methods, such as dietary control and increased physical activity, have low patient compliance and are ineffective for moderate to severe metabolic disorders [15][18]. - These methods are likened to "blocking" strategies in flood control, which may provide short-term results but fail to address the underlying issues [18][21]. Group 3: Innovative Solutions - The dual-target weight loss drug, Ma Shidu Tie, inspired by ancient flood control wisdom, aims to tackle obesity through a combination of activating GCG and GLP-1 receptors [27][29]. - Activation of GCG receptors helps reduce liver fat content, while GLP-1 receptor activation decreases appetite and increases satiety, effectively managing energy intake [30][31]. Group 4: Clinical Outcomes - Clinical studies indicate that Ma Shidu Tie can lead to a weight reduction of up to 21%, an 80% decrease in liver fat content, a reduction in waist circumference by 11 cm, and a neck circumference reduction of 3 cm [35][37]. - The drug also improves multiple metabolic indicators, including blood uric acid, blood pressure, and blood lipids, demonstrating its multifaceted efficacy [39][41].